People with atrial fibrillation (AFib) and obesity may have fewer episodes of AFib after ablation if they take the diabetes medication metformin in addition to standard care, according to a preliminary, late-breaking science presentation Sunday at the American Heart Association’s Scientific Sessions 2025. The meeting, held Nov. 7–10 in New Orleans, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
This article was originally published on MedicalXpress.com
